208 related articles for article (PubMed ID: 24563017)
21. Insulin Glargine U100 Improved Glycemic Control and Reduced Nocturnal Hypoglycemia in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3 and 4.
Betônico CC; Titan SMO; Lira A; Pelaes TS; Correa-Giannella MLC; Nery M; Queiroz M
Clin Ther; 2019 Oct; 41(10):2008-2020.e3. PubMed ID: 31383366
[TBL] [Abstract][Full Text] [Related]
22. [Comparison between basal insulin glargine and NPH insulin in patients with diabetes type 1 on conventional intensive insulin therapy].
Pesić M; Zivić S; Radenković S; Velojić M; Dimić D; Antić S
Vojnosanit Pregl; 2007 Apr; 64(4):247-52. PubMed ID: 17580534
[TBL] [Abstract][Full Text] [Related]
23. Comparison of glycemic variability associated with insulin glargine and intermediate-acting insulin when used as the basal component of multiple daily injections for adolescents with type 1 diabetes.
White NH; Chase HP; Arslanian S; Tamborlane WV;
Diabetes Care; 2009 Mar; 32(3):387-93. PubMed ID: 19106380
[TBL] [Abstract][Full Text] [Related]
24. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.
Rosenstock J; Fonseca V; McGill JB; Riddle M; Hallé JP; Hramiak I; Johnston P; Davis M
Diabetologia; 2009 Sep; 52(9):1778-88. PubMed ID: 19526210
[TBL] [Abstract][Full Text] [Related]
25. Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.
Murphy NP; Keane SM; Ong KK; Ford-Adams M; Edge JA; Acerini CL; Dunger DB
Diabetes Care; 2003 Mar; 26(3):799-804. PubMed ID: 12610040
[TBL] [Abstract][Full Text] [Related]
26. A retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patients.
Dhital SM; Shenker Y; Meredith M; Davis DB
Endocr Pract; 2012; 18(5):712-9. PubMed ID: 22784834
[TBL] [Abstract][Full Text] [Related]
27. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
Rosenstock J; Park G; Zimmerman J;
Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
[TBL] [Abstract][Full Text] [Related]
28. Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis.
Toyoda M; Kimura M; Yamamoto N; Miyauchi M; Umezono T; Suzuki D
J Nephrol; 2012; 25(6):989-95. PubMed ID: 22307438
[TBL] [Abstract][Full Text] [Related]
29. Therapy in type 2 diabetes: insulin glargine vs. NPH insulin both in combination with glimepiride.
Eliaschewitz FG; Calvo C; Valbuena H; Ruiz M; Aschner P; Villena J; Ramirez LA; Jimenez J;
Arch Med Res; 2006 May; 37(4):495-501. PubMed ID: 16715577
[TBL] [Abstract][Full Text] [Related]
30. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes.
Ashwell SG; Amiel SA; Bilous RW; Dashora U; Heller SR; Hepburn DA; Shutler SD; Stephens JW; Home PD
Diabet Med; 2006 Mar; 23(3):285-92. PubMed ID: 16492212
[TBL] [Abstract][Full Text] [Related]
31. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes.
Linn T; Fischer B; Soydan N; Eckhard M; Ehl J; Kunz C; Bretzel RG
J Clin Endocrinol Metab; 2008 Oct; 93(10):3839-46. PubMed ID: 18611975
[TBL] [Abstract][Full Text] [Related]
32. Omitting breakfast and lunch after injection of different long-acting insulin preparations at bedtime: a prospective study in patients with type 2 diabetes.
Wiesli P; Krayenbühl P; Uthoff H; Seifert B; Schmid C
Diabetologia; 2009 Sep; 52(9):1816-9. PubMed ID: 19565212
[TBL] [Abstract][Full Text] [Related]
33. Comparison of insulin glargine versus NPH insulin in people with Type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin.
Siegmund T; Weber S; Blankenfeld H; Oeffner A; Schumm-Draeger PM
Exp Clin Endocrinol Diabetes; 2007 Jun; 115(6):349-53. PubMed ID: 17701878
[TBL] [Abstract][Full Text] [Related]
34. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes.
Massi Benedetti M; Humburg E; Dressler A; Ziemen M
Horm Metab Res; 2003 Mar; 35(3):189-96. PubMed ID: 12734781
[TBL] [Abstract][Full Text] [Related]
35. Short-term effects of NPH insulin, insulin detemir, and insulin glargine on the GH-IGF1-IGFBP axis in patients with type 1 diabetes.
Ma Z; Christiansen JS; Laursen T; Lauritzen T; Frystyk J
Eur J Endocrinol; 2014 Oct; 171(4):471-9. PubMed ID: 25005937
[TBL] [Abstract][Full Text] [Related]
36. Predictors of early discontinuation of basal insulin therapy in type 2 diabetes in primary care.
Kostev K; Dippel FW; Rathmann W
Prim Care Diabetes; 2016 Apr; 10(2):142-7. PubMed ID: 26324105
[TBL] [Abstract][Full Text] [Related]
37. Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents--a randomized, prospective, crossover, open clinical trial.
Hermanns N; Kulzer B; Kohlmann T; Jacob S; Landgraf W; Theobald K; Haak T
Health Qual Life Outcomes; 2015 Jun; 13():77. PubMed ID: 26055391
[TBL] [Abstract][Full Text] [Related]
38. [Comparison on efficacy and safety of two regimens for treatment of type 2 diabetes mellitus: glargine plus metformin versus neutral protamine hagedorn plus metformin].
Hu M; Luo Y; Zhang L; Yang X; Zhang H
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2010 Jun; 27(3):622-5. PubMed ID: 20649032
[TBL] [Abstract][Full Text] [Related]
39. A randomised, open-labelstudy of insulin glargine or neutral protamine Hagedorn insulin in Chinese paediatric patients with type 1 diabetes mellitus.
Liu M; Zhou Z; Yan J; Li P; Song W; Fu J; Chen X; Zhao W; Xi L; Luo X; Sha L; Deng X; Gong C
BMC Endocr Disord; 2016 Nov; 16(1):67. PubMed ID: 27887605
[TBL] [Abstract][Full Text] [Related]
40. Replacing Insulin Glargine with Neutral Protamine Hagedorn (NPH) Insulin in a Subpopulation of Study Subjects in the Action to Control Cardiovascular Risk in Diabetes (ACCORD): Effects on Blood Glucose Levels, Hypoglycemia and Patient Satisfaction.
Berard L; Cameron B; Woo V; Stewart J
Can J Diabetes; 2015 Aug; 39(4):296-301. PubMed ID: 25819531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
